Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 7/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039822 | 0.85 | TACR1 (0.55) | CTSLCASP1CTSBCTSKCTSS | |
| SCHEMBL14488100 | 0.85 | TACR1 (0.55) | CTSLCASP1CTSBCTSKCTSS | |
| SCHEMBL5689118 | 0.85 | TACR1 (0.55) | CTSLCASP1CTSBCTSKCTSS | |
| SCHEMBL8208600 | 0.81 | CTSB (0.56) | CTSLCASP1CTSBCTSKCTSS | |
| SCHEMBL19203668 | 0.79 | TACR1 (0.56) | CTSLCASP1CTSBCTSKCTSS | |
| SCHEMBL15080871 | 0.79 | TACR1 (0.68) | CTSLCTSBCTSKCTSSTACR1 | |
| SCHEMBL10977849 | 0.78 | ITGB3 (0.57) | CTSLCASP1CTSBCTSKCTSS | |
| SCHEMBL10753165 | 0.76 | CTSL (0.51) | CTSLCTSBCTSKCTSSTACR1 | |
| SCHEMBL7151822 | 0.76 | ALDH1A1 (0.74) | CTSLCTSBCTSKCTSSTACR1 | |
| SCHEMBL329686 | 0.76 | ALDH1A1 (0.74) | CTSLCTSBCTSKCTSSTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723307-B2 | Amino acid derivatives and pharmaceutical uses thereof | ASTON UNIVERSITY (GB) | 2010-05-25 | — | — | US | disclosed |
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | ASTON UNIVERSITY (GB) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | F3, IL4I1, TPMT | CTSL 2160/4885CASP1 709/4885CTSB 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.